Unicycive(US:UNCY)2026-03-30 11:29Financial Performance - Net loss attributable to common stockholders for the year ended December 31, 2025, was $26.6 million, or $1.67 per share, a decrease from a net loss of $37.8 million, or $5.65 per share, in 2024[7] - Total operating expenses for the year ended December 31, 2025, were $29.5 million, down from $32.1 million in 2024[17] - The change in fair value of the warrant liability resulted in other income of $2.0 million for the year ended December 31, 2025, compared to an expense of $5.8 million in 2024[16] Cash and Assets - As of March 30, 2026, the company reported unaudited cash, cash equivalents, and marketable securities totaling $54.9 million, providing a runway into 2027[8] - Total assets increased to $49.1 million as of December 31, 2025, from $31.7 million in 2024[15] - Stockholders' equity rose to $30.2 million as of December 31, 2025, compared to $7.4 million in 2024[15] Expenses - Research and Development (R&D) expenses decreased to $9.1 million for the year ended December 31, 2025, from $20.0 million in 2024, primarily due to reduced drug development and clinical trial costs[5] - General and Administrative (G&A) expenses increased to $20.4 million for the year ended December 31, 2025, compared to $12.1 million in 2024, driven by higher consulting and commercial launch preparation costs[6] - Total operating expenses for the year ended December 31, 2025, were $29.5 million, down from $32.1 million in 2024[17] Regulatory and Commercial Activities - The FDA accepted the resubmission of the New Drug Application (NDA) for oxylanthanum carbonate (OLC), with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026[10] - The company is preparing for a potential commercial launch of OLC in the third quarter of 2026, with ongoing commercial readiness activities[9]